Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC007 for chronic kidney disease–associated pruritus in hemodialysis patients
ChiCTR2500108031Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine liposome in pruritus and end-stage kidney disease (ESKD) (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: Responder rate for WI-NRS improvement at week 12. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
bupivacaine liposome
03
Conditions
pruritusend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2500108031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108031.